Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.
作者信息
Duret Pierre-Marie, Sebbag Eden, Mallick Auriane, Gravier Simon, Spielmann Lionel, Messer Laurent
机构信息
Department of Rheumatology, Hôpitaux Civils de Colmar, Colmar, Alsace, France
Department of Rheumatology-Centre National de Référence des Maladies Systémiques Rares Est Sud-Ouest (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
出版信息
Ann Rheum Dis. 2020 Sep;79(9):1251-1252. doi: 10.1136/annrheumdis-2020-217362. Epub 2020 Apr 30.
Abstract
摘要
相似文献
1
Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept.使用肿瘤坏死因子-α抑制剂依那西普治疗的脊柱关节炎患者从新冠肺炎中康复。
Ann Rheum Dis. 2020 Sep;79(9):1251-1252. doi: 10.1136/annrheumdis-2020-217362. Epub 2020 Apr 30.
2
Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina .对梅西纳的《关于使用肿瘤坏死因子-α抑制剂依那西普治疗的脊柱关节炎患者从新冠病毒感染中康复的通信。关于一名接受乌司奴单抗治疗的银屑病关节炎新冠病毒感染患者的报告》的回复
Ann Rheum Dis. 2021 May;80(5):e80. doi: 10.1136/annrheumdis-2020-218147. Epub 2020 Aug 18.
3
[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].[一名接受羟氯喹和抗TNFα治疗的炎性风湿性疾病患者感染了新型冠状病毒]
Pan Afr Med J. 2020 Aug 5;35(Suppl 2):134. doi: 10.11604/pamj.supp.2020.35.134.25011. eCollection 2020.
4
TNFα inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis.TNFα 抑制剂可能对重症 COVID-19 有效：从中毒性表皮坏死松解症中得到的启示。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620926800. doi: 10.1177/1753466620926800.
5
Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.关于“使用肿瘤坏死因子-α抑制剂依那西普治疗的脊柱关节炎患者从新冠病毒感染中康复。一例接受乌司奴单抗治疗的银屑病关节炎合并新冠病毒感染患者的报告”的通信
Ann Rheum Dis. 2021 May;80(5):e79. doi: 10.1136/annrheumdis-2020-218029. Epub 2020 Aug 18.
6
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.以病例为基础的综述：使用司库奇尤单抗治疗的强直性脊柱炎患者的 2019 年冠状病毒病（COVID-19）。
Rheumatol Int. 2020 Oct;40(10):1707-1716. doi: 10.1007/s00296-020-04635-z. Epub 2020 Jun 26.
7
Olfactory and Gustatory Dysfunction in a COVID-19 Patient with Ankylosing Spondylitis Treated with Etanercept: Case Report.COVID-19 患者伴中轴型脊柱关节炎使用依那西普治疗后出现嗅觉味觉障碍：病例报告。
J Korean Med Sci. 2020 Jun 1;35(21):e201. doi: 10.3346/jkms.2020.35.e201.
8
Biologics, spondylitis and COVID-19.生物制剂、脊柱炎与新型冠状病毒肺炎
Ann Rheum Dis. 2020 Dec;79(12):1663-1665. doi: 10.1136/annrheumdis-2020-217941. Epub 2020 Jun 10.
9
Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy.评估抗 TNF 治疗的强直性脊柱炎患者 COVID-19 的频率和强度。
Turk J Med Sci. 2022 Apr;52(2):522-523. doi: 10.55730/1300-0144.5341. Epub 2022 Apr 14.
10
How to manage rheumatic patients during the coronavirus pandemic.如何在新冠疫情期间管理风湿病患者。
Panminerva Med. 2020 Sep;62(3):176-177. doi: 10.23736/S0031-0808.20.03935-X. Epub 2020 Apr 28.
引用本文的文献
1
A Three-Dimensional Xeno-Free Culture Condition for Wharton's Jelly-Mesenchymal Stem Cells: The Pros and Cons.三维无动物来源培养条件对牙髓间充质干细胞：利弊分析。
Int J Mol Sci. 2023 Feb 13;24(4):3745. doi: 10.3390/ijms24043745.
2
Immune responses in mildly versus critically ill COVID-19 patients.轻症与重症 COVID-19 患者的免疫反应。
Front Immunol. 2023 Jan 30;14:1077236. doi: 10.3389/fimmu.2023.1077236. eCollection 2023.
3
Carotenoids as potential inhibitors of TNFα in COVID-19 treatment.类胡萝卜素作为 COVID-19 治疗中 TNFα 的潜在抑制剂。
PLoS One. 2022 Dec 27;17(12):e0276538. doi: 10.1371/journal.pone.0276538. eCollection 2022.
4
The role of interleukin-22 in lung health and its therapeutic potential for COVID-19.白细胞介素-22 在肺部健康中的作用及其在 COVID-19 治疗中的潜力。
Front Immunol. 2022 Jul 27;13:951107. doi: 10.3389/fimmu.2022.951107. eCollection 2022.
5
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions.新冠病毒感染中的炎症通路：机制与治疗干预措施
MedComm (2020). 2022 Aug 1;3(3):e154. doi: 10.1002/mco2.154. eCollection 2022 Sep.
6
Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond.病毒感染与全身炎症：COVID-19 及其他疾病带来的启示。
Cells. 2022 Jul 14;11(14):2198. doi: 10.3390/cells11142198.
7
Clinical outcomes of patients with COVID-19 and inflammatory rheumatic diseases receiving biological/targeted therapy.COVID-19 患者接受生物/靶向治疗的临床结局。
Ann Saudi Med. 2022 May-Jun;42(3):155-164. doi: 10.5144/0256-4947.2022.155. Epub 2022 Jun 2.
8
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients.抗风湿药物可能改善类风湿关节炎患者COVID-19的临床病程及结局。
Mediterr J Rheumatol. 2022 Mar 31;33(1):68-74. doi: 10.31138/mjr.33.1.68. eCollection 2022 Mar.
9
Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm.新冠病毒的免疫特征：细胞因子风暴的深入原因及后果。
Int J Mol Sci. 2022 Apr 20;23(9):4545. doi: 10.3390/ijms23094545.
10
The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections.细胞因子和趋化因子在严重急性呼吸综合征冠状病毒 2 感染中的作用。
Front Immunol. 2022 Apr 7;13:832394. doi: 10.3389/fimmu.2022.832394. eCollection 2022.
本文引用的文献
1
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.迫切需要开展针对新型冠状病毒肺炎的抗肿瘤坏死因子疗法试验。
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
2
The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic.COVID-19 全球风湿病联盟：大流行期间的数据收集。
Nat Rev Rheumatol. 2020 Jun;16(6):293-294. doi: 10.1038/s41584-020-0418-0.
3
COVID-19 infection and rheumatoid arthritis: Faraway, so close!COVID-19 感染与类风湿关节炎：远在天边，近在咫尺！
Autoimmun Rev. 2020 May;19(5):102523. doi: 10.1016/j.autrev.2020.102523. Epub 2020 Mar 20.
4
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
5
TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.
Curr Med Res Opin. 2004 Jan;20(1):39-40. doi: 10.1185/030079903125002757.
6
Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.肿瘤坏死因子受体：Fc融合蛋白治疗感染性休克。可溶性肿瘤坏死因子受体脓毒症研究组。
N Engl J Med. 1996 Jun 27;334(26):1697-702. doi: 10.1056/NEJM199606273342603.
Zotero 插件